The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression

Autor: Littlepage, LE, Adler, AS, Kouros-Mehr, H, Huang, G, Chou, J, Krig, SR, Griffi th, OL, Korkola, JE, Qu, K, Lawson, DA, Xue, Q, Sternlicht, MD, Dijkgraaf, GJP, Yaswen, P, Rugo, HS, Sweeney, CA, Collins, CC, Gray, JW, Chang, HY, Werb, Z

Publikováno v: Cancer discovery, vol 2, iss 7
Littlepage, LE; Adler, AS; Kouros-Mehr, H; Huang, G; Chou, J; Krig, SR; et al.(2012). The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discovery, 2(7), 638-651. doi: 10.1158/2159-8290.CD-12-0093. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/7xs7c1z4

The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3836b58d04c39e978dd1b4997db9b4ea
https://escholarship.org/uc/item/7xs7c1z4